Skip to content
value.today

NextCure, Inc.

🇺🇸 Germantown, Maryland, USABiotechnologyFounded 2015
Total raised
$108 M
2 rounds on record
Latest round
$93 M
Nov 2018
First round on record
Dec 2015
Today
Went public
See the company page

NextCure, Inc. is listed today as NextCure, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of NextCure, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$22 MPrivate placement after listing$10 to $50 million

NextCure, Inc.: Private sale, Nov 2025

Investors in this round

12 investors had bought by the notice of Dec 10, 2025: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for NextCure, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
$1,215,001
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kevin G. Shaw · Executive Officer
  • Michael Richman · Executive Officer, Director
  • Sourav G. Kundu · Executive Officer
  • Steven P. Cobourn · Executive Officer
  • Timothy G. Mayer · Executive Officer
  • Udayan G. Guha · Executive Officer
  • Anne G. Borgman · Director
  • David P. Kabakoff · Director
  • Elaine V. Jones · Director
  • Ellen G. Feigal · Director
  • John G. Houston · Director
  • Stephen G. Webster · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 000000375) · New York, New YorkSold in IL, MA, NY, TX

Remarks in the notice

  • On fees: “The placement agent received at closing a cash fee equal to a percentage of the aggregate consideration plus certain expenses.”

Signed by Michael Richman, President and CEO. Source: SEC Form D, newest notice filed Dec 10, 2025. Read the notice at the SEC.

equity, optionsSEC
Nov 2018$93 MNo. 2$50 to $250 million

NextCure, Inc.: Raise no. 2, Nov 2018

Investors in this round

22 investors had bought by the notice of Nov 19, 2018: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for NextCure, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$93 M of $93 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series B Preferred and Common Stock issuable upon the conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kevin N. Heller · Executive Officer · Chief Medical Officer
  • Michael Richman · Executive Officer, Director · President & Chief Executive Officer
  • Steven Cobourn · Executive Officer · Chief Financial Officer
  • Chau Q. Khuong · Director
  • David Kabakoff · Director
  • Elaine N. Jones · Director
  • Judith Li · Director
  • Michael Yi · Director
  • Stella Xu · Director
  • Tim Q. Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Richman, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 19, 2018. Read the notice at the SEC.

equity, optionsSEC
Dec 2015$15 MNo. 1$10 to $50 million

NextCure, Inc.: Raise no. 1, Dec 2015

Investors in this round

7 investors had bought by the notice of Jan 11, 2016: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for NextCure, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $67 M offered; $52 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series A Preferred Stock and the Common Stock issuable upon the conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Asher Rubin · Executive Officer
  • Michael Richman · Executive Officer, Director
  • Carolyn Green · Director
  • Chau Q. Khuong · Director
  • David Kabakoff · Director
  • Judith Q. Li · Director
  • Tim Q. Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Richman, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 11, 2016. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • NextCure, Inc. had no revenue when it filed its newest notice of a funding round (Dec 2025).

    SEC Form D (revenue range) · Dec 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2025

Products and services#

No products or services of NextCure, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in NextCure, Inc.
InvestorKindAmountRoundRoleSource
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Canaan Partners X LLCFund or asset managernot statednot statedHeld Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Canaan X L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A-1, A-2, A-3 and B-1 preferred (Form 3, 2019)SEC Form 3
OrbiMed Capital GP VI LLCFund or asset managernot statednot statedHeld Series A-1, A-2, A-3 and B-1 preferred (Form 3, 2019)SEC Form 3
Quan Venture Fund II, L.P.Venture capitalnot statednot statedHeld Series B-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Sofinnova Management IX, L.L.C.Fund or asset managernot statednot statedHeld Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Sofinnova Venture Partners IX, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, A-3 and B-1 preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 22 investors.

Largest shareholders today

Institutions holding NextCure, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by NextCure, Inc.
NameRoleNamed in
Kevin G. ShawExecutive officerDec 2025
Michael RichmanExecutive officerDec 2025
Sourav G. KunduExecutive officerDec 2025
Steven P. CobournExecutive officerDec 2025
Timothy G. MayerExecutive officerDec 2025
Udayan G. GuhaExecutive officerDec 2025
Kevin N. HellerChief Medical OfficerNov 2018
Steven CobournChief Financial OfficerNov 2018
Asher RubinExecutive officerJan 2016
Anne G. BorgmanDirectorDec 2025
David P. KabakoffDirectorDec 2025
Elaine V. JonesDirectorDec 2025
Ellen G. FeigalDirectorDec 2025
John G. HoustonDirectorDec 2025
Michael RichmanDirectorDec 2025
Stephen G. WebsterDirectorDec 2025
Chau Q. KhuongDirectorNov 2018
David KabakoffDirectorNov 2018
Elaine N. JonesDirectorNov 2018
Judith LiDirectorNov 2018
Michael YiDirectorNov 2018
Stella XuDirectorNov 2018
Tim Q. ShannonDirectorNov 2018
Carolyn GreenDirectorJan 2016
Judith Q. LiDirectorJan 2016

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.